In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections

Ocular Immunology and Inflammation

Volumn 14, Issue 6, 2006, Pages 347-351

  Ozdek, Sengul C ^a,b   Miller, Darlene ^a,c   Flynn, Patrick M ^a   Flynn Jr , Harry W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b GAZI UNIVERSITY   (Turkey)

^c NONE   (United States)

Author keywords

Fluoroquinolones; In vitro antifungal activity

Indexed keywords

AGAR; GATIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SABOURAUD AGAR;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; COLONY FORMING UNIT; CONTROLLED STUDY; DILUTION; DRUG EFFICACY; ENDOPHTHALMITIS; EYE INFECTION; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; KERATITIS; NONHUMAN;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CANDIDA; COLONY COUNT, MICROBIAL; EYE INFECTIONS, FUNGAL; FLUOROQUINOLONES; HUMANS; QUINOLINES; RETROSPECTIVE STUDIES;

EID: 33845680984     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940600976953     Document Type: Article

References (28)

1. Essman TF, Flynn HW Jr., Smiddy WE, et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers. 1997;28:185-194.
2. Schiedler V, Scott IU, Flynn HW Jr., Davis JL, Benz MS, Miller D. Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol. 2004;137:725-731.
3. Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol. 2004;137:820-825.
4. Binder MI, Chua J, Kaiser PK, Procop GW, Isada CM. Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine. 2003;82:97-105.
5. Narang S, Gupta A, Gupta V, et al. Fungal endophthalmitis following cataract surgery: clinical presentation, microbiological spectrum, and outcome. Am J Ophthalmol. 2001;132:609-617.
6. Bharathi MJ, Ramakrishnan R, Vasu S, et al. Epidemiological characteristics and laboratory diagnosis of fungal keratitis: a three-year study. Indian J Ophthalmol. 2003;51:315-321.
7. Scott IU, Flynn HW Jr., Feuer W, et al. Endophthalmitis associated with microbial keratitis. Ophthalmology. 1996;103(11):1864-1870.
8. Tanure MA, Cohen EJ, Sudesh S, et al. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. Cornea. 2000;19:307-312.
9. Manzouri B, Vafidis GC, Wyse RK. Pharmacotherapy of fungal eye infections. Expert Opin Pharmacother. 2001;2:1849-1857.
10. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466.
11. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136(3):500-505.
12. Mah FS. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol. 2004;15:316-320.
13. Shen L, Mitscher LA, Sharma PN, O'Donnell TJ, Chu DWT, et al. Mechanism of inhibition of DNA gyrase by quinolone antibacterials. A cooperative drug-DNA binding model. Biochemistry. 1989;28:2886-2894.
14. Figgitt DP, Denyer SP, Dewick PM, Jackson DE, Williams P. Topoisomerase II: a potential target for novel antifungal agents. Biochem Biophys Res Commun. 1989 14;160:257-262.
15. Shen LL, Fostel JM. DNA topoisomerase inhibitors as antifungal agents. Adv Pharmacol. 1994;29B:227-244.
16. Nakajima R, Kitamura A, Someya K, Tanaka M, Sato K. In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob Agents Chemother. 1995;39:1517-1521.
17. Sugar AM, Liu XP, Chen RJ. Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs. Antimicrob Agents Chemother. 1997;41:2518-2521.
18. Rupp D, Reeves T, Kapadia S, Anger C. Use of 48-hour zone inhibition assay to test the antimicrobial preservative efficacy of Zymar™ and Vigamox™ against yeast isolates (published abstract). ARVO 2004.
19. Todd V, Herrygers L, Noecker R. Comparison of effectiveness of Vigamox™ Zymar™ against Aspergillus fumigatus and Candida albicans. (published abstract). ARVO 2004.
20. Quinolone can combat 22 new pathogens. www.onlinepressroom.net/alcon/new/
21. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991;324:384-394.
22. Gupta AK, Ahmad I, Summerbell RC. Fungicidal activities of commonly used disinfectants and antifungal pharmaceutical spray preparations against clinical strains of Aspergillus and Candida species. Med Mycol. 2002;40:201-208.
23. Kolodynski J, Ulaszewski S, Grobelny D, Witkowska R, Witek S, Lachowicz T. Effect of some quaternary benzylammonium salts on physiology of yeast. Acta Microbiol Pol. 1984;33:119-130.
24. Batoosingh AL, Lee E, Welty DF, Tang-Liu D. Gatifloxacin 0.3% vs. ciprofloxacin 0.35%: Ocular pharmacokinetics profile following topical application in rabbits (published abstract). IOVS 2003.
25. Katz HR, Masket S, Lane SS, et al. Human aqueous humor penetration pharmacokinetics of moxifloxacin after topical administration of moxifloxacin 0.5% ophthalmic solution (published abstract). OMIG 2003.
26. McCulley JP, Surratt G, Shine W. Fourth generation fluoroquinolone penetration into aqueous humor in humans: Post-op concentrations (published abstract). IOVS 2004.
27. Solomon R, Donnenfeld E, Perry H, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor (published abstract). IOVS 2004.
28. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.